Last Updated: August 25, 2026

CLINICAL TRIALS PROFILE FOR DARZALEX

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for DARZALEX

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01415882 ↗	Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib	Recruiting	National Cancer Institute (NCI)	Phase 2	2012-01-31	This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01415882 ↗	Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib	Recruiting	Mayo Clinic	Phase 2	2012-01-31	This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01592370 ↗	An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma	Active, not recruiting	Janssen, LP	Phase 1/Phase 2	2012-08-02	The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for DARZALEX

Condition Name

Chart
Table

Condition Name for DARZALEX
Intervention	Trials
Multiple Myeloma	35
Plasma Cell Myeloma	12
Recurrent Plasma Cell Myeloma	10
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for DARZALEX
Intervention	Trials
Multiple Myeloma	61
Neoplasms, Plasma Cell	58
Lymphoma	8
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for DARZALEX

Trials by Country

Map
Table

Trials by Country for DARZALEX
Location	Trials
United States	283
Canada	18
Italy	8
France	7
Germany	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for DARZALEX
Location	Trials
Minnesota	22
New York	17
California	17
North Carolina	15
Massachusetts	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for DARZALEX

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for DARZALEX
Clinical Trial Phase	Trials
PHASE3	3
PHASE1	2
Phase 4	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for DARZALEX
Clinical Trial Phase	Trials
Recruiting	50
Active, not recruiting	17
Not yet recruiting	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DARZALEX

Sponsor Name

Chart
Table

Sponsor Name for DARZALEX
Sponsor	Trials
National Cancer Institute (NCI)	22
Mayo Clinic	10
Janssen Scientific Affairs, LLC	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for DARZALEX
Sponsor	Trials
Other	94
Industry	76
NIH	22
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.